{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch31506\stshfhich31506\stshfbi31506\deflang16393\deflangfe16393\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fbidi \fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}
{\f3\fbidi \froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f10\fbidi \fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f34\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria Math;}
{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fhimajor\f31502\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria;}{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f279\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\f280\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\f282\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\f283\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\f284\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\f285\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f286\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\f287\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\f299\fbidi \fmodern\fcharset238\fprq1 Courier New CE;}
{\f300\fbidi \fmodern\fcharset204\fprq1 Courier New Cyr;}{\f302\fbidi \fmodern\fcharset161\fprq1 Courier New Greek;}{\f303\fbidi \fmodern\fcharset162\fprq1 Courier New Tur;}{\f304\fbidi \fmodern\fcharset177\fprq1 Courier New (Hebrew);}
{\f305\fbidi \fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f306\fbidi \fmodern\fcharset186\fprq1 Courier New Baltic;}{\f307\fbidi \fmodern\fcharset163\fprq1 Courier New (Vietnamese);}{\f619\fbidi \froman\fcharset238\fprq2 Cambria Math CE;}
{\f620\fbidi \froman\fcharset204\fprq2 Cambria Math Cyr;}{\f622\fbidi \froman\fcharset161\fprq2 Cambria Math Greek;}{\f623\fbidi \froman\fcharset162\fprq2 Cambria Math Tur;}{\f626\fbidi \froman\fcharset186\fprq2 Cambria Math Baltic;}
{\f627\fbidi \froman\fcharset163\fprq2 Cambria Math (Vietnamese);}{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}
{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fhimajor\f31528\fbidi \froman\fcharset238\fprq2 Cambria CE;}
{\fhimajor\f31529\fbidi \froman\fcharset204\fprq2 Cambria Cyr;}{\fhimajor\f31531\fbidi \froman\fcharset161\fprq2 Cambria Greek;}{\fhimajor\f31532\fbidi \froman\fcharset162\fprq2 Cambria Tur;}
{\fhimajor\f31535\fbidi \froman\fcharset186\fprq2 Cambria Baltic;}{\fhimajor\f31536\fbidi \froman\fcharset163\fprq2 Cambria (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}
{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31573\fbidi \fswiss\fcharset177\fprq2 Calibri (Hebrew);}{\fhiminor\f31574\fbidi \fswiss\fcharset178\fprq2 Calibri (Arabic);}{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}
{\fhiminor\f31576\fbidi \fswiss\fcharset163\fprq2 Calibri (Vietnamese);}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;
\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\chyperlink\ctint255\cshade255\red0\green0\blue255;}{\*\defchp \f31506\fs22 }{\*\defpap \ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 \styrsid9975749 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*
\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\sa200\sl276\slmult1
\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af31506\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang16393\langfe16393\cgrid\langnp16393\langfenp16393 \snext11 \ssemihidden \sunhideused Normal Table;}{
\s15\ql \li720\ri0\sa200\sl276\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin720\itap0\contextualspace \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 
\sbasedon0 \snext15 \sqformat \spriority34 \styrsid9975749 List Paragraph;}{\*\cs16 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \ul\cf17 \sbasedon10 \sunhideused \styrsid9975749 Hyperlink;}{\*\cs17 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 
\sbasedon10 \spriority0 \styrsid9975749 hlfld-contribauthor;}{\*\cs18 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \sbasedon10 \spriority0 \styrsid9975749 nlm_given-names;}{\*\cs19 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \sbasedon10 \spriority0 \styrsid9975749 
nlm_article-title;}{\*\cs20 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \sbasedon10 \spriority0 \styrsid9975749 nlm_fpage;}{\*\cs21 \additive \rtlch\fcs1 \af0 \ltrch\fcs0 \sbasedon10 \spriority0 \styrsid9975749 nlm_lpage;}{\*\cs22 \additive \rtlch\fcs1 \af0 
\ltrch\fcs0 \sbasedon10 \spriority0 \styrsid9975749 reflink-block;}}{\*\listtable{\list\listtemplateid-1649113850\listhybrid{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext
\leveltemplateid-1995253410\'01-;}{\levelnumbers;}\loch\af0\hich\af0\dbch\af0\fbias0 \fi-360\li720\lin720 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693
\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li2160\lin2160 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}
\f3\fbias0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li3600\lin3600 }
{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li4320\lin4320 }{\listlevel\levelnfc23\levelnfcn23
\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li5040\lin5040 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0
\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0
\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li6480\lin6480 }{\listname ;}\listid553852245}{\list\listtemplateid1518905772\listhybrid{\listlevel\levelnfc2\levelnfcn2\leveljc0\leveljcn0\levelfollow0
\levelstartat1\levelspace0\levelindent0{\leveltext\leveltemplateid-1703231782\'03(\'00);}{\levelnumbers\'02;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fbias0 \fi-720\li1440\lin1440 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1
\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698713\'02\'01.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li1800\lin1800 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative
\levelspace0\levelindent0{\leveltext\leveltemplateid67698715\'02\'02.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li2520\lin2520 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0
\levelindent0{\leveltext\leveltemplateid67698703\'02\'03.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li3240\lin3240 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0
{\leveltext\leveltemplateid67698713\'02\'04.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li3960\lin3960 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698715\'02\'05.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li4680\lin4680 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698703\'02\'06.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li5400\lin5400 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698713\'02\'07.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li6120\lin6120 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698715\'02\'08.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li6840\lin6840 }{\listname ;}\listid777261417}{\list\listtemplateid-619281582\listhybrid{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0
\levelstartat0\levelspace0\levelindent0{\leveltext\leveltemplateid-1995253410\'01-;}{\levelnumbers;}\loch\af0\hich\af0\dbch\af0\fbias0 \fi-360\li720\lin720 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative
\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li2160\lin2160 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698689
\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 
\fi-360\li3600\lin3600 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li4320\lin4320 }{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li5040\lin5040 }{\listlevel\levelnfc23\levelnfcn23\leveljc0
\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1
\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li6480\lin6480 }{\listname ;}\listid1426727300}{\list\listtemplateid1063298182\listhybrid{\listlevel\levelnfc23\levelnfcn23
\leveljc0\leveljcn0\levelfollow0\levelstartat0\levelspace0\levelindent0{\leveltext\leveltemplateid943984660\'01-;}{\levelnumbers;}\loch\af0\hich\af0\dbch\af0\fbias0 \fi-360\li720\lin720 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0
\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0
\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li2160\lin2160 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691
\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 
\fi-360\li4320\lin4320 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li5040\lin5040 }{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0
\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li6480\lin6480 }{\listname ;}\listid1603605790}{\list\listtemplateid-245094766\listhybrid{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li2700\lin2700 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0
\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li3420\lin3420 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative
\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li4140\lin4140 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0
{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li4860\lin4860 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691
\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li5580\lin5580 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 
\fi-360\li6300\lin6300 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li7020\lin7020 }{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li7740\lin7740 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0
\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li8460\lin8460 }{\listname ;}\listid1931696223}{\list\listtemplateid1315471936\listhybrid{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\leveltemplateid67698701\'01\u-3844 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0
\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li2160\lin2160 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative
\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0
{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691
\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li4320\lin4320 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 
\fi-360\li5040\lin5040 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698689\'01\u-3913 ?;}{\levelnumbers;}\f3\fbias0 \fi-360\li5760\lin5760 }{\listlevel
\levelnfc23\levelnfcn23\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698691\'01o;}{\levelnumbers;}\f2\fbias0 \fi-360\li6480\lin6480 }{\listlevel\levelnfc23\levelnfcn23\leveljc0\leveljcn0
\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698693\'01\u-3929 ?;}{\levelnumbers;}\f10\fbias0 \fi-360\li7200\lin7200 }{\listname ;}\listid2041126484}{\list\listtemplateid636932754\listhybrid{\listlevel
\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\leveltemplateid67698703\'02\'00.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fbias0 \fi-360\li720\lin720 }{\listlevel\levelnfc4\levelnfcn4
\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698713\'02\'01.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li1440\lin1440 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2
\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698715\'02\'02.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li2160\lin2160 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0
\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698703\'02\'03.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li2880\lin2880 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1
\lvltentative\levelspace0\levelindent0{\leveltext\leveltemplateid67698713\'02\'04.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li3600\lin3600 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative
\levelspace0\levelindent0{\leveltext\leveltemplateid67698715\'02\'05.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li4320\lin4320 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0
\levelindent0{\leveltext\leveltemplateid67698703\'02\'06.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li5040\lin5040 }{\listlevel\levelnfc4\levelnfcn4\leveljc0\leveljcn0\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0
{\leveltext\leveltemplateid67698713\'02\'07.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-360\li5760\lin5760 }{\listlevel\levelnfc2\levelnfcn2\leveljc2\leveljcn2\levelfollow0\levelstartat1\lvltentative\levelspace0\levelindent0{\leveltext
\leveltemplateid67698715\'02\'08.;}{\levelnumbers\'01;}\rtlch\fcs1 \af0 \ltrch\fcs0 \fi-180\li6480\lin6480 }{\listname ;}\listid2041389485}}{\*\listoverridetable{\listoverride\listid1603605790\listoverridecount0\ls1}{\listoverride\listid553852245
\listoverridecount0\ls2}{\listoverride\listid777261417\listoverridecount0\ls3}{\listoverride\listid2041126484\listoverridecount0\ls4}{\listoverride\listid1931696223\listoverridecount0\ls5}{\listoverride\listid1426727300\listoverridecount0\ls6}
{\listoverride\listid2041389485\listoverridecount0\ls7}}{\*\revtbl {Unknown;}{Amit Kumar Dinda;}}{\*\rsidtbl \rsid686259\rsid1458323\rsid1531754\rsid2259114\rsid2705019\rsid3173547\rsid4863132\rsid5791797\rsid5912346\rsid6433215\rsid7539566\rsid7886406\rsid7947207\rsid9120589\rsid9319092
\rsid9393738\rsid9975749\rsid11414305\rsid15429107\rsid15823405}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\author Author}{\operator MD}
{\creatim\yr2021\mo3\dy19\hr15\min23}{\revtim\yr2021\mo3\dy19\hr15\min23}{\version2}{\edmins0}{\nofpages19}{\nofwords4134}{\nofchars23564}{\nofcharsws27643}{\vern57433}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl1440\margr1440\margt1440\margb1440\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont1\relyonvml0\donotembedlingdata0\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1440\dgvorigin1440\dghshow1\dgvshow1
\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\viewnobound1\snaptogridincell\allowfieldendsel
\wrppunct\asianbrkrule\rsidroot9975749\newtblstyruls\nogrowautofit\usenormstyforlist\noindnmbrts\felnbrelev\nocxsptable\indrlsweleven\noafcnsttbl\afelev\utinl\hwelev\spltpgpar\notcvasp\notbrkcnstfrctbl\notvatxbx\krnprsnet\cachedcolbal \nouicompat \fet0
{\*\wgrffmtfilter 2450}\nofeaturethrottle1\ilfomacatclnup0\ltrpar \sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sectrsid9319092\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2
\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang 
{\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid9120589 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 
\f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Global Regulations of Regenerative Medicine and Cell-based Therapy
\par Review Article
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 \page 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Abstract
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 The convergenc
e of basic and translational sciences has led to a boom in interdisciplinary research and innovations across various healthcare, technology, and artificial intelligence-related fields. The goal of such advances is to improve health by integrating science 
and technology. Novel diagnostic and therapeutic strategies in healthcare can be grouped under the umbrella of }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 \'93Emerging Technologies in Medicine.
\'94 }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Regenerative medicine is one such emerging technology, which can be defined as an interdisciplinary platform 
of biology, medicine, and material and engineering sciences involving therapeutic modalities for regeneration, repair, and replacement of tissues or organs. }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 However, several gaps exist in the existing knowledge for bedside clinical application of such moda
lities in terms of quality, safety, and efficacy, which need to be addressed for successful utilization of such advances. This review provides an overview of the global regulatory guidelines pertaining to Regenerative Medicine and Cell-based Therapy.

\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 Keywords:}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 
 Cell-based therapy, Global, Regenerative medicine, Regulations
\par \page 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Introduction
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 
Advances in medicine have changed the scenario of the prevention and treatment of diseases. In current times, convergence of basic and translational sciences and technology
 has resulted in rapid interdisciplinary cutting-edge research and innovation in the fields of biomedicine, biotechnology, genetics, nanotechnology, robotics, and artificial intelligence. All these advances aim to enhance avenues for diagnosis and treatme
nt of diseases, thereby improving health. These novel innovative products and processes in health care grouped under \'93Emerging Technology in Medicine\'94
 are going to revolutionize and replace current health care practices in the near future. However, several 
gaps exist in the existing knowledge for bedside clinical application of these products in terms of quality, safety, and efficacy, which need to be addressed for successful utilization of such advances. Maximizing the benefits and minimizing risks associa
ted with novel technologies depend on the quality of data for regulatory assessment, policies, governance, standards, assessment of risk-benefit ratio, and incentives that shape the development and deployment of these emerging technologies.
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Regenerative med
icine (RM) is one such emerging technology, which does not have a universally accepted definition. However, it can be defined as an interdisciplinary platform of biology, medicine, and material and engineering sciences involving therapeutic modalities for
 
regeneration, repair, and replacement of tissues or organs. RM, which includes stem cell therapy, tissue engineering, and other cell-based therapies, has attracted the attention of the scientific and clinical community as well as public interest owing to 
t
heir significant therapeutic potential in reducing morbidity and mortality along with regaining function of damaged or diseased organs. The hope of utilizing endogenous repair mechanisms in the treatment of various degenerative, acute/chronic debilitating
 diseases raises the probable applications of RM based therapy. Though initially the term \'93stem cell therapy\'94
 was popular and several authors used is interchangeably with RM, there are large number of interventions which do not involve use of stem cell. The
refore, RM includes various other modalities for regeneration and repair under its broad heading. Stem cells are the primitive cells that are capable of self-renewal and have the ability to differentiate into specific cell types. In addition, these cells 
are also known to possess paracrine properties and biological plasticity that modulate the local and systemic environment of the body to address the root cause of pathologies. 
\par }\pard \ltrpar\ql \li0\ri0\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Need for regulations
\par }\pard \ltrpar\ql \fi720\li0\ri0\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Innovations in regenerative medicine and stem cell therapy 
have enabled the growth of a global market of treatments for a wide range of diseases; however, the majority of this market operates outside the domain of orthodox forms of governance of medical therapeutics}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid15429107  (1)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . In argument, orthodox models of governance state that national and transnational regulations have failed to impose appropriate standards on the 
\lquote illicit\rquote  supply of stem cell therapies}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid15429107  (2)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
. These models also state that the practice-based model of stem cell innovation used by stem cell clinics should be regarded as unproved, unsafe and illegitimate. Consumers who wish to avail such therapies and products are viewed as ill-informed \lquote 
stem cell tourists}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid15429107  (3)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .\rquote 
 Such consumers are considered to be subjected to the exploitative character of the market and restricted in their ability to make informed choices.
\par The negative criticism may be attributed to media publicity, by the providers, regarding the effectiveness of these forms of therapies without a sound scientific rationale, oversight, and patient protecti
on rights. The quest for new cures has fostered large consumer expectations. In addition, the increase in global demand for such new forms of therapies also stems from the limitations in domestically available health-care facilities. Furthermore, supplier
s of these therapies enhance consumer expectations with highly positive information regarding the science stating ineffectiveness of existing conventional forms of therapies.
\par Broadly, two stem cell innovation models exist. The first, being followed predomin
antly by western countries, involves all five stages of basic research, clinical experimentation, product development, clinical trial, and product approval prior to commercial release of the product. On the other hand, in the second model (as followed in 
Japan and the European Union), hospital exemption or other national provisions may be permitted for use of stem cells in specific cases}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid15429107  (2)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 . The need of the hour is facilitation of the second model, in a regulated manner in order to fast track the process o
f approval for stem cell therapies in specific indications. Genetic disorders, spinal cord/traumatic brain injuries, neurological conditions (especially childhood onset conditions) are indications that require prompt and early action in order to reduce th
e severity/extent of damage.
\par Regulatory guidelines, standards, and policies must be framed based on the source of cells: allogeneic, autologous; homologous/non-homologous use. Formal authorization of stem cell therapy at a national level is required, keepin
g in mind the need of the procedure in comparison with the effectiveness of existing therapeutic modalities. The goal should be to constitute an example of medical innovation for the benefit of the patient, with scientifically generalizable validated resu
lts in terms of quality, safety, efficacy, and performance. To support this, as per the statement by the International Society for Cell Therapy (ISCT) (2010), \lquote 
Medical innovation in cellular therapy may be viewed as the ethical and legitimate use of non-approved cell therapy by qualified health-care professionals in their practice of medicine}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid15429107  (4)}{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .\rquote  More recently, the International Cellular Medicine Society (ICMS) (2016) defines it as \lquote the clinical application of innovative therapy that is based upon good pat
ient care, is intended to improve or ameliorate an individual patient\rquote s condition and evidences a reasonable chance of success for the patient being treated}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid15429107  (5)}{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7539566 \rquote }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\super\insrsid9975749\charrsid9975749 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Such medical innovation is regarded as a form of practice, not research, and therefore, the g
overnance falls within the normal regulation of the professional standards of medical practice by licensing bodies and medical malpractice laws and not within the purview of science}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid15429107  (6)}{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . The need of the hour is standard regulatory guidelines that are unifo
rm across all domains of governance according to the types of interventions. A broader viewpoint pertaining to consumer rights and stem cell innovation is that patients and their families or partners should have the right to seek treatment for their disea
s
es. There should be no law that withholds the fundamental right unless there is a considerable probability of harm to the patient. The ultimate goal is to create an alliance between the two markets, research for validation of quality and safety efficacy; 
and clinical applications, in order to ensure timely and smooth delivery of medical innovations such as stem cell and other therapies under RM.
\par Several stem cell products (autologous and allogeneic) have received approval from the US FDA. A comprehensive gu
ide detailing the exact requirements of the approval process, quality control, research laboratory, and clinical set-up must be published in order to ensure streamlining of stem cell innovation.
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 
Organizations involved in regulation of Regenerative Medicine and Cell Based Therapy}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}}\pard\plain \ltrpar\s15\ql \fi-360\li720\ri0\sa200\sl480\slmult1
\widctlpar\wrapdefault\faauto\ls1\rin0\lin720\itap0\pararsid9120589\contextualspace \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Food and Drug Administration (FDA)
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}World Health Organization (WHO)
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}International Society of Stem Cell Research (ISSCR)
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}Indian Council of Medical Research (ICMR)
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}Department of Biotechnology, Govt. of India (DBT)
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}International Cellular Medicine Society (ICMS)
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}International Society for Stem Cell Therapy (ICST)
\par }\pard\plain \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Regulatory affairs
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
Regulations for bench to bedside translation of stem cell treatments are currently under renegotiation. A key issue in this field is that
 existing regulatory approaches for the clinical testing and commercial approval of new drugs do not efficiently translate onto stem cell interventions. The ISSCR, recently published the }{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 
\i\f0\fs24\insrsid9975749\charrsid9975749 Guidelines for Stem Cell Research and Clinical Translation}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 , and stated that \lquote 
cell based medical products should rarely if ever be developed outside of a formal clinical trials process}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid15429107  (7)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .}{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7886406 \rquote }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
 However, the group acknowledged that clinicians may be justified in attempting medically innovative stem cell-based interventions in a 
small number of seriously ill patients, in some very limited cases to generate data and document the safety and efficacy of the therapy.
\par Currently, the regulatory landscape of stem cell research is a conflict between two central dynamics: the striving for 
international harmonization and an increasing process of regulatory diversification. In-depth research is required into the (changing) regulatory conditions of drug regulatory authorities. Regulatory norms for stem cell therapy are further complicated due
 to use of different types of cells often regulated by different government agencies and different regulatory requirements and rules.
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Global regulations for regenerative medicine and stem cell therapy

\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 United States of America (USA)}{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\super\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Two categories of regulat
ions exist for cell based therapy in the USA: 351 and 361 The 351 category includes cells that are more than minimally manipulated and those used in a non-homologous manner. These cells are classified as a biological drug product and they are subject to U
S Food and Drug Administration (FDA) pre-market approval. The guidelines state that 351 biological products must \lquote by law [\'85
] go through the multi-phase drug pipeline approval process starting after pre-clinical studies with an Investigational New Drug (IND) application and proceeding to Phase 1 trials\rquote  and then to Phase II and III trials}{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid686259  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . 
\par However, three types of regulatory exceptions exist for this category of cells, which aim at}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 : 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 (i)\tab}}\pard\plain \ltrpar\s15\ql \fi-720\li1440\ri0\sa200\sl480\slmult1
\widctlpar\wrapdefault\faauto\ls3\rin0\lin1440\itap0\pararsid9120589\contextualspace \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Speeding up the transition from preclinical to clinical testing (fast track approval),
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 (ii)\tab}
Accelerated authorization of phase I and II clinical trials that involve seriously ill patients with low life expectancy (accelerated approval), and
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 (iii)\tab}More rapid clinical testing of \lquote breakthrough therapies\rquote 
 that have the potential to treat a serious or potentially life threatening disease (breakthrough therapy designation).
\par }\pard\plain \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 In addition, priority review aims to expedite the duration of the evaluation process that precedes market approval of a new drug (six instead of ten month
s), after the completion of the clinical trial period. A fifth regulatory exception is the \'93expanded access\'94 program (also called \'93compassionate use program\'94
), which provides patients access to investigational new treatments parallel to (but outside of) FDA-approved phase II and III clinical trials}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 .
\par The second is the 361 category, which regulates the use of minimally manipulated stem cells applied for homologous use. Cells that fall under this category are not subject to pre-market approval by the FDA a
nd can be used in patients under compliance with the US human tissue regulation}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 European Union (EU)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\b\f0\fs24\super\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
The guidelines for stem cell treatments in the EU are similar to that in the USA. Cells that are more than minimally manipulated and used in non-homologous contexts are defined as \'93medicinal products\'94 and are regulated under the }{\rtlch\fcs1 
\ai\af0\afs24 \ltrch\fcs0 \i\f0\fs24\insrsid9975749\charrsid9975749 Advanced Therapy Medicinal Products }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
(ATMP) legislation, which was issued by the European Medicines Agency (EMA)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
. Minimally manipulated autologous stem cells, on the other han
d, are regulated under the human tissue legislations of European member states, and not centrally under EMA. The EMA regulation demands evidence from systematic clinical studies, typically from multiphase trials.
\par A \'93compassionate use\'94 program exists, which allows access to new drugs and biological products (including stem cell products) outside of premarket clinical trials. In addition, the EMA has also introduced a so-called \'93hospital exemption\'94
 program for stem cell interventions. This program allows the provision of cellular medicinal products to individual patients \'93in a European hospital under the exclusive professional responsibility of a doctor.\'94 More recently, the EMA introduced a 
\'93conditional market approval\'94 scheme, which can be extended for stem c
ell interventions. According to this scheme, a stem cell product can be licensed at a later stage of a phase III trial, when data collection for efficacy and safety has almost been completed}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (8)}
{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Japan}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\b\f0\fs24\super\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
Japan is spearheading a campaign that has formed the starting point of a radical regulatory reform for stem cell therapy- the Regenerati}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259 ve Medicine Promotion Act (RMPA) (9)}{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\cf0\revised\revauth1\revdttm-1484711047\insrsid9975749\charrsid9975749  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 The RMPA was followed by the passing of the Amended Pharmaceutical Affairs Law, which went into effect in November 2014.
\par The amended law allowed for conditional, limited-term market approval of stem cell products after early-phase clinical trials. Conditional approval may be granted with positive clinical data from as few as t
en patients that predict the safety and efficacy of the tested cell products. Interventions approved under this scheme are eligible for reimbursement by the Japanese health insurance system (70:30 between state and patients). Japan has two cell products i
n the market, namely Autologous cultured epidermis (JACE) and Autologous cultured cartilage (JACC)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (9)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 South Korea}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\b\f0\fs24\super\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
The South Korean government supports stem cell research like any other biomedical research. }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 The Bioethics and Safety Act is the main law, whi
ch came into effect on Jan 1, 2005, regulates human stem cell research}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid686259  (10,11)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 . However, the act is not all-inclusive and has unclear provisions that raised queries regarding the effectiveness of the guidelines.\~The aspect that raised most concerns regardi
ng malpractice was the experimental research conducted by Hwang, who attempted to clone human embryos for their stem cells. The Bioethics Act (as of 2013) is considered a primary reference, which attempts to navigate both ethics and scientific innovation,
 and to protect individuals from the exploitation that may happen in a laboratory setting.
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Cell therapy products (CTP) in South Korea are also regulated as biologics, which are overseen by the Ministry of Food and Drug Safety (MFDS) under the Pharmaceutical
 Affairs Act (1953, amended 2010)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (10,11)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 
CTPs are defined as a medical product manufactured through physical, chemical, or biological manipulation, such as in vitro culture of autologous, allogeneic, or xenogenic cells. Minimal manipulation of autologous
 or allogeneic cells (simple separation, washing, freezing, thawing, and other manipulations, while maintaining the biological properties) are exempted from the guidelines}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid686259  (10,11)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 .
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 This Act limits the dispensing of drugs to pharmacists and drug manufacturi
ng to license-holders, which are obtained only after an Investigative New Drug (IND) application and clinical evaluation of safety and efficacy data. No exemptions exist for physicians to produce drugs that fall within the scope of this act without a}{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259 n IND or a manufacturer\rquote s licens}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 e}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (10,11)}{
\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
Currently, three CTPs have been approved for marketing in South Korea; however, these products are not available for marketing outside of the country. The products are stem cell-based products that have been approved ba
sed on efficacy studies with on relatively small sample sizes, compared to those required for approval of other pharmaceutical drugs. Cupistem, which is an autologous adipose-derived cell therapy, has been approved for treatment of anal fistulas based on 
c
linical data from 33 patients. Cartistem is an allogeneic, umbilical cord blood-derived cell therapy approved for damaged knee cartilage from data on 89 patients. Similarly, Heartcellgram is a cultured, autologous bone marrow-derived MSC product approved 
for use in myocardial infarctions based on a sample size of 59 patients}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid686259  (10,11)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 South America}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\b\f0\fs24\super\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
South American countries face distinct challenges in the regulation of stem cells therapies. In Argentina, national regulatory authorities have legal power only when medical products cross provincial borders or are involved in foreign trade}{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
. As a result, federal regulations are not applicable at the provincial level as long as medical treatments or services are applied exclusively within the geographic jurisdic
tion of a province. On the other hand, development of a regulatory framework for clinical stem cell research in Brazil has been challenging for two reasons: religious opposition to stem cell research, and a constitutional prohibition that bans the commerc
ial use of human cells and tissues. Brazilian constitution prohibits the commercialization of human body materials, including human cells and their derivatives}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (8)}{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .
\par The clinical use of stem cells in Argentina is currently regulated under the Ministerial Res
olution No. 610/2007 from the Argentinean Ministry of Health. According to this resolution, use of human cells falls under the authority of the Unique Central Institute for Ablation and Implantation (INCUCAI)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid7947207  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . As per the INCUCAI norms, stem cell interv
entions are not governed as a medical product, but as a medical procedure, which are managed by the Argentinean Transplant Act. Therefore, with the exception of haematopoietic cell transplants from human bone marrow, all types of stem cells are considered
 experimental and require evaluation of safety and efficacy through clinical research}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (8)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 
Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \b\f0\fs24\super\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
The United States Department of Health and Human Services, FDA finalized the guidance document of the Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use in November/December 
2017}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (12, 13)}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
. The guidance represents the current viewpoint of the FDA on the topic of stem cell therapy. Based on this guidance, }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
human cells, tissues, and cellular and tissue-based products (HCT/P)}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
are defined in 21 CFR 1271.3(d) as articles containing or
 consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. Owing to the unique nature of HCT/Ps, the FDA proposed and in 2005 implemented a tiered, risk-based approach to the re
gulation of HCT/Ps}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (12, 13)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .
\par The article suggests that HCT/Ps include, but are not limited to, bone, ligament, skin, dura mater, heart valve, cornea, hematopoietic stem/progenitor cells derived from peripheral and cord blood, manipulated autologous chondroc
ytes, epithelial cells on a synthetic matrix, and semen or other reproductive tissue}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (12, 13)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
. The following articles are not considered HCT/Ps: 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 (1) Vascularized human organs for transplantation; 
\par (2) Whole Blood or blood components or blood derivative products subject to listing under 21 CFR Parts 607 and 207, respectively; 
\par (3) Secreted or extracted human products, such as milk, collagen, and cell factors, except that semen is considered an HCT/P; 
\par (4) Minimally manipulated bone marrow for homologous use
 and not combined with another article (except for water, crystalloids, or a sterilizing, preserving, or storage agent, if the addition of the agent does not raise new clinical safety concerns with respect to the bone marrow); 
\par (5) Ancillary products used in the manufacture of HCT/P; 
\par (6) Cells, tissues, and organs derived from animals other than humans; 
\par (7) In vitro diagnostic products as defined in 21 CFR 809.3(a); and 
\par (8) Blood vessels recovered with an organ, as defined in 42 CFR 121.2 that are intended for use in organ transplantation and labeled \'93For use in organ transplantation only.\'94 (21 CFR 1271.3(d))}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
The FDA is authorized to apply the requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act) t
o those products that meet the definition of drug, biologic, or device, under this tiered, risk-based approach. However, the HCT/Ps that meet specific criteria or fall within detailed exceptions do not require premarket review and approval}{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (12, 13)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .
\par An HCT/P is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 if it meets all of the following criteria (21 CFR 1271.10(a))}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (12, 13)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 : 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}}\pard\plain \ltrpar\s15\ql \fi-360\li720\ri0\sa200\sl480\slmult1
\widctlpar\wrapdefault\faauto\ls2\rin0\lin720\itap0\pararsid9120589\contextualspace \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 The HCT/P is minimally manipulated; 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}The HCT/P is intended for homologous use only, as reflected by th
e labeling, advertising, or other indications of the manufacturer\rquote s objective intent; 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}
The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preservin
g, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}Either: 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \f10\lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \loch\af10\dbch\af0\hich\f10 \'fc\tab}}\pard \ltrpar\s15\ql \fi-360\li1440\ri0\sa200\sl480\slmult1
\widctlpar\wrapdefault\faauto\ls4\rin0\lin1440\itap0\pararsid9120589\contextualspace {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 The HCT/P does not have a systemic effect and 
is not dependent upon the metabolic activity of living cells for its primary function; or 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \f10\lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \loch\af10\dbch\af0\hich\f10 \'fc\tab}
The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and: 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \f3\lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \loch\af3\dbch\af0\hich\f3 \'b7\tab}}\pard \ltrpar\s15\ql \fi-360\li2700\ri0\sa200\sl480\slmult1
\widctlpar\wrapdefault\faauto\ls5\rin0\lin2700\itap0\pararsid9120589\contextualspace {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Is for autologous use; 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \f3\lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \loch\af3\dbch\af0\hich\f3 \'b7\tab}Is for allogeneic use in a first-degree or second-degree blood relative; or 

\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \f3\lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \loch\af3\dbch\af0\hich\f3 \'b7\tab}Is for reproductive use.
\par }\pard\plain \ltrpar\ql \fi360\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 As defined in 21 CFR 1271.3(f), minimal manipulation refers to:
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}}\pard\plain \ltrpar\s15\ql \fi-360\li720\ri0\sa200\sl480\slmult1
\widctlpar\wrapdefault\faauto\ls6\rin0\lin720\itap0\pararsid9120589\contextualspace \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Structural tissues: Processing that does not alter the original relevant characteristics of the tissue relating to the tissue\rquote s utility for reconstruction, repair, or replacement; 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 -\tab}
Cells or nonstructural tissues: Processing that does not alter the relevant biological characteristics of cells or tissues. 
\par }\pard\plain \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \fi360\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 As defined in 21 CFR 1271.3(c), homologous u
se refers to the repair, reconstruction, replacement, or supplementation of a recipient\rquote s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor.
\par HCT/Ps that are regulated as biological products a
re subject to section 351 of the PHS Act and the FD&C Act and require premarket approval. In order to lawfully market a biological product, a biologics license must be obtained (PHS Act) (42 U.S.C. 262(a)). The licenses are issued after a determination by
 
the FDA that the establishment(s) and the biological products meet the applicable requirements to ensure the continued safety, purity, and potency of such products (21 CFR 601.2(d)). For clinical studies of investigational drug products, the sponsor must 
have an IND application in effect in accordance with the FD&C Act (21 U.S.C. 355(i)) and FDA regulations (21 CFR Part 312 and 21 CFR 601.21)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid7947207  (12, 13)}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 .
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 Conclusion
\par }\pard \ltrpar\ql \fi720\li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
The way forward would be to establish a collaborative partnership or an association between pri
vate and public sectors to exchange data pertaining to quality safety and efficacy of the therapy. The collective effort of these organizations would help to develop guidelines for  IRB approval and interact with the national regulatory bodies for develop
i
ng regulatory policies facilitating widespread clinical trials. Subsequently, accreditation of therapies/products, with periodic enhancements in standards may prove the best option empowering India as a major force in the global arena of Regenerative Medi
cine with considerable social and economic impact{\*\bkmkstart _GoBack}{\*\bkmkend _GoBack}.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid4863132 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid4863132\charrsid5791797 Disclosure statement:
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4863132 This manuscript is a concise review of the published works on regulations in regenerative medicine, worldwide. Considering that the guidelines are standard statements
, the text is predominantly verbatim. The aim is to provide an overview of }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid6433215 the }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4863132 
global guidelines in one article for better understanding.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid11414305  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9393738 All sourc}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid2705019 
es have been cited in the }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid1531754 reference list.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid4863132\charrsid9975749 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 \page 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \b\f0\fs24\insrsid9975749\charrsid9975749 References
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 1.\tab}}\pard\plain \ltrpar\s15\ql \fi-360\li720\ri0\sl480\slmult1
\widctlpar\wrapdefault\faauto\ls7\rin0\lin720\itap0\pararsid9120589\contextualspace \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Lee TL, Lysaght T, Lipworth Y, Hendl T, Kerridge I, Munsie M, et al. Regulating the stem cell industry: needs and responsibilities. Bulletin of the World Health Organization }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 2017; }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \i\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 95}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749  : 663-4.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 2.\tab}
Salter B, Zhou Y, Datta S.Governing new global health-care markets: the case of stem cell treatments. New Political Economy 2017; }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \i\f0\fs24\insrsid9975749\charrsid9975749 22}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749  : 76-91.
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \cs17\lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 3.\tab}}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs17\f0\fs24\insrsid9975749\charrsid9975749 Barclay }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs18\f0\fs24\insrsid9975749\charrsid9975749 E.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749  }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs19\f0\fs24\insrsid9975749\charrsid9975749 Stem-cell experts raise concerns about medical tourism}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .\~}{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Lancet}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749  2009; }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \i\f0\fs24\insrsid9975749\charrsid9975749 373}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749  :\~}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs20\f0\fs24\insrsid9975749\charrsid9975749 883}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 \endash }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs21\f0\fs24\insrsid9975749\charrsid9975749 4}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .\~
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \cs17\lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 4.\tab}}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs17\f0\fs24\insrsid9975749\charrsid9975749 Gunter }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs18\f0\fs24\insrsid9975749\charrsid9975749 KC}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 ,\~
Caplan AL, Mason C, Salzman R, Janssen WE, Nichols K, }{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 et al}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs19\f0\fs24\insrsid9975749\charrsid9975749 ISCT White Paper \endash  Cell Therapy Medical Tourism: Time for Action}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 .\~}{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Cytotherapy}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749  2010; }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \i\f0\fs24\insrsid9975749\charrsid9975749 12}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749  : }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs20\f0\fs24\insrsid9975749\charrsid9975749 965}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 \endash }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs21\f0\fs24\insrsid9975749\charrsid9975749 7.
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 5.\tab}}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
International Cellular Medicine Society. Basic Tenets of Cell Based Medicine. 2016. Available from:\~}{\field\fldedit{\*\fldinst {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid15823405 
HYPERLINK "http://www.cellmedicinesociety.org/attachments/370_Section%201%20Basic%20Tenets%20of%20Cell%20Based%20Medicine.pdf"}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid1458323\charrsid15823405 {\*\datafield 
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90be200000068007400740070003a002f002f007700770077002e00630065006c006c006d00650064006900630069006e00650073006f00630069006500740079002e006f00720067002f00610074007400610063006800
6d0065006e00740073002f003300370030005f00530065006300740069006f006e00200031002000420061007300690063002000540065006e0065007400730020006f0066002000430065006c006c0020004200610073006500640020004d00650064006900630069006e0065002e007000640066000000795881f43b1d7f
48af2c825dc485276300000000a5ab00030000}}}{\fldrslt {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \cs16\f0\fs24\insrsid9975749\charrsid15823405 http://www.cellmedicinesociety.org/attachments/370_Section%201%20Basic%20Tenets%20of%20Cell%20Based%20Medicine.pdf}}}
\sectd \ltrsect\linex0\endnhere\sectlinegrid360\sectdefaultcl\sectrsid9319092\sftnbj {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 6.\tab}
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, US Department of Health, Education and Welfare. }{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
Ethical Principles and Guidelines for the Protection of Human Subjects of Research}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . 1979. Belmont Report.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\cs22\f0\fs24\insrsid9975749\charrsid9975749 \~
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 7.\tab}}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 
\f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 Skokie IL, International Society for Stem Cell Research.\~}{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 \f0\fs24\chbrdr\brdrnone\brdrframe1 
\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 Guidelines for the Clinical Translation of Stem Cells}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749  2008.}{\rtlch\fcs1 \af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 8.\tab}Rosemann A, Bortz G, Vasen F, Sleeboom-Faulkner M. }{\rtlch\fcs1 \ab\af0\afs24 
\ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations. Regen Med 2016; }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\i\f0\fs24\insrsid9975749\charrsid9975749 11}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 : 647-57.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \ab\af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 9.\tab}}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Kusakabe T. Regulatory updates on cellular therapy products in Japan. International Society for Cellular Therapy 2013}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \ab\af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 10.\tab}}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Joung J. Regulatory updates on cell and gene therapy products in Korea. Ministry of Food and Drug Safety.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \ab\af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 11.\tab}}{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 Lysaght T}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 . Cellular therapies: Regulating uncertainty in Asia\rquote s biomedical hubs. Asian Bioethics Review 2014; }{\rtlch\fcs1 
\af0\afs24 \ltrch\fcs0 \i\f0\fs24\insrsid9975749\charrsid9975749 6 }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 : 234-45.
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 12.\tab}Center for Biologics Evaluation and 
Research, Center for Devices and Radiological Health. }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. }{\rtlch\fcs1 \ai\af0\afs24 \ltrch\fcs0 \f0\fs24\chshdng0\chcfpat0\chcbpat8\insrsid9975749\charrsid9975749 
Guidance for Industry and Food and Drug Administration Staff. July 2020}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par {\listtext\pard\plain\ltrpar \s15 \rtlch\fcs1 \af0 \ltrch\fcs0 \lang1033\langfe1033\langnp1033\langfenp1033\insrsid9975749\charrsid9975749 \hich\af0\dbch\af0\loch\f0 13.\tab}
Bedford P & Gillham-Eisen LA (Health Canada), with input from representatives at United States Food and Drug Administration (US FDA); Singapore Health Sciences Authority (HSA); European Medicines Association (EMA); Health Canada; Korean Ministry of 
Food and Drug Safety (MFDS); Japanese Pharmaceuticals and Medical Devices Agency (PMDA); Chinese Taipei Food and Drug Administration (FDA); Australian Therapeutic Goods Administration (TGA); New Zealand Medsafe }{\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 International Regulatory Perspectives: Degree of Regulatory Oversight for Eight Categories of Cell Therapy Products. 2013.}{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par }\pard\plain \ltrpar\ql \li0\ri0\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 \rtlch\fcs1 \af0\afs22\alang1025 \ltrch\fcs0 \f31506\fs22\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \ab\af0\afs24 \ltrch\fcs0 
\f0\fs24\insrsid9975749\charrsid9975749 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\faauto\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par }\pard \ltrpar\ql \li0\ri0\sa200\sl480\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0\pararsid9120589 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid9975749\charrsid9975749 
\par 
\par }{\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \f0\fs24\insrsid3173547\charrsid9975749 
\par }{\*\themedata 504b030414000600080000002100e9de0fbfff0000001c020000130000005b436f6e74656e745f54797065735d2e786d6cac91cb4ec3301045f748fc83e52d4a
9cb2400825e982c78ec7a27cc0c8992416c9d8b2a755fbf74cd25442a820166c2cd933f79e3be372bd1f07b5c3989ca74aaff2422b24eb1b475da5df374fd9ad
5689811a183c61a50f98f4babebc2837878049899a52a57be670674cb23d8e90721f90a4d2fa3802cb35762680fd800ecd7551dc18eb899138e3c943d7e503b6
b01d583deee5f99824e290b4ba3f364eac4a430883b3c092d4eca8f946c916422ecab927f52ea42b89a1cd59c254f919b0e85e6535d135a8de20f20b8c12c3b0
0c895fcf6720192de6bf3b9e89ecdbd6596cbcdd8eb28e7c365ecc4ec1ff1460f53fe813d3cc7f5b7f020000ffff0300504b030414000600080000002100a5d6
a7e7c0000000360100000b0000005f72656c732f2e72656c73848fcf6ac3300c87ef85bd83d17d51d2c31825762fa590432fa37d00e1287f68221bdb1bebdb4f
c7060abb0884a4eff7a93dfeae8bf9e194e720169aaa06c3e2433fcb68e1763dbf7f82c985a4a725085b787086a37bdbb55fbc50d1a33ccd311ba548b6309512
0f88d94fbc52ae4264d1c910d24a45db3462247fa791715fd71f989e19e0364cd3f51652d73760ae8fa8c9ffb3c330cc9e4fc17faf2ce545046e37944c69e462
a1a82fe353bd90a865aad41ed0b5b8f9d6fd010000ffff0300504b0304140006000800000021006b799616830000008a0000001c0000007468656d652f746865
6d652f7468656d654d616e616765722e786d6c0ccc4d0ac3201040e17da17790d93763bb284562b2cbaebbf600439c1a41c7a0d29fdbd7e5e38337cedf14d59b
4b0d592c9c070d8a65cd2e88b7f07c2ca71ba8da481cc52c6ce1c715e6e97818c9b48d13df49c873517d23d59085adb5dd20d6b52bd521ef2cdd5eb9246a3d8b
4757e8d3f729e245eb2b260a0238fd010000ffff0300504b03041400060008000000210096b5ade296060000501b0000160000007468656d652f7468656d652f
7468656d65312e786d6cec594f6fdb3614bf0fd87720746f6327761a07758ad8b19b2d4d1bc46e871e698996d850a240d2497d1bdae38001c3ba618715d86d87
615b8116d8a5fb34d93a6c1dd0afb0475292c5585e9236d88aad3e2412f9e3fbff1e1fa9abd7eec70c1d1221294fda5efd72cd4324f1794093b0eddd1ef62fad
79482a9c0498f184b4bd2991deb58df7dfbb8ad755446282607d22d771db8b944ad79796a40fc3585ee62949606ecc458c15bc8a702910f808e8c66c69b9565b
5d8a314d3c94e018c8de1a8fa94fd05093f43672e23d06af89927ac06762a049136785c10607758d9053d965021d62d6f6804fc08f86e4bef210c352c144dbab
999fb7b4717509af678b985ab0b6b4ae6f7ed9ba6c4170b06c788a705430adf71bad2b5b057d03606a1ed7ebf5babd7a41cf00b0ef83a6569632cd467faddec9
699640f6719e76b7d6ac355c7c89feca9cccad4ea7d36c65b258a206641f1b73f8b5da6a6373d9c11b90c537e7f08dce66b7bbeae00dc8e257e7f0fd2badd586
8b37a088d1e4600ead1ddaef67d40bc898b3ed4af81ac0d76a197c86826828a24bb318f3442d8ab518dfe3a20f000d6458d104a9694ac6d88728eee2782428d6
0cf03ac1a5193be4cbb921cd0b495fd054b5bd0f530c1931a3f7eaf9f7af9e3f45c70f9e1d3ff8e9f8e1c3e3073f5a42ceaa6d9c84e5552fbffdeccfc71fa33f
9e7ef3f2d117d57859c6fffac327bffcfc793510d26726ce8b2f9ffcf6ecc98baf3efdfdbb4715f04d814765f890c644a29be408edf3181433567125272371be
15c308d3f28acd249438c19a4b05fd9e8a1cf4cd296699771c393ac4b5e01d01e5a30a787d72cf1178108989a2159c77a2d801ee72ce3a5c545a6147f32a9979
3849c26ae66252c6ed637c58c5bb8b13c7bfbd490a75330f4b47f16e441c31f7184e140e494214d273fc80900aedee52ead87597fa824b3e56e82e451d4c2b4d
32a423279a668bb6690c7e9956e90cfe766cb37b077538abd27a8b1cba48c80acc2a841f12e698f13a9e281c57911ce298950d7e03aba84ac8c154f8655c4f2a
f074481847bd804859b5e696007d4b4edfc150b12addbecba6b18b148a1e54d1bc81392f23b7f84137c2715a851dd0242a633f900710a218ed715505dfe56e86
e877f0034e16bafb0e258ebb4faf06b769e888340b103d3311da9750aa9d0a1cd3e4efca31a3508f6d0c5c5c398602f8e2ebc71591f5b616e24dd893aa3261fb
44f95d843b5974bb5c04f4edafb95b7892ec1108f3f98de75dc97d5772bdff7cc95d94cf672db4b3da0a6557f70db629362d72bcb0431e53c6066acac80d699a
6409fb44d08741bdce9c0e4971624a2378cceaba830b05366b90e0ea23aaa241845368b0eb9e2612ca8c742851ca251ceccc70256d8d87265dd96361531f186c
3d9058edf2c00eafe8e1fc5c509031bb4d680e9f39a3154de0accc56ae644441edd76156d7429d995bdd88664a9dc3ad50197c38af1a0c16d684060441db0256
5e85f3b9660d0713cc48a0ed6ef7dedc2dc60b17e92219e180643ed27acffba86e9c94c78ab90980d8a9f0913ee49d62b512b79626fb06dccee2a432bbc60276
b9f7dec44b7904cfbca4f3f6443ab2a49c9c2c41476dafd55c6e7ac8c769db1bc399161ee314bc2e75cf8759081743be1236ec4f4d6693e5336fb672c5dc24a8
c33585b5fb9cc24e1d4885545b58463634cc5416022cd19cacfccb4d30eb45296023fd35a458598360f8d7a4003bbaae25e331f155d9d9a5116d3bfb9a95523e
51440ca2e0088dd844ec6370bf0e55d027a012ae264c45d02f708fa6ad6da6dce29c255df9f6cae0ec38666984b372ab5334cf640b37795cc860de4ae2816e95
b21be5ceaf8a49f90b52a51cc6ff3355f47e0237052b81f6800fd7b802239daf6d8f0b1571a8426944fdbe80c6c1d40e8816b88b8569082ab84c36ff0539d4ff
6dce591a26ade1c0a7f669880485fd484582903d284b26fa4e2156cff62e4b9265844c4495c495a9157b440e091bea1ab8aaf7760f4510eaa69a6465c0e04ec6
9ffb9e65d028d44d4e39df9c1a52ecbd3607fee9cec7263328e5d661d3d0e4f62f44acd855ed7ab33cdf7bcb8ae889599bd5c8b3029895b6825696f6af29c239
b75a5bb1e6345e6ee6c28117e73586c1a2214ae1be07e93fb0ff51e133fb65426fa843be0fb515c187064d0cc206a2fa926d3c902e907670048d931db4c1a449
59d366ad93b65abe595f70a75bf03d616c2dd959fc7d4e6317cd99cbcec9c58b34766661c7d6766ca1a9c1b327531486c6f941c638c67cd22a7f75e2a37be0e8
2db8df9f30254d30c1372581a1f51c983c80e4b71ccdd28dbf000000ffff0300504b0304140006000800000021000dd1909fb60000001b010000270000007468
656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73848f4d0ac2301484f78277086f6fd3ba109126dd88d0add40384e4
350d363f2451eced0dae2c082e8761be9969bb979dc9136332de3168aa1a083ae995719ac16db8ec8e4052164e89d93b64b060828e6f37ed1567914b284d2624
52282e3198720e274a939cd08a54f980ae38a38f56e422a3a641c8bbd048f7757da0f19b017cc524bd62107bd5001996509affb3fd381a89672f1f165dfe5141
73d9850528a2c6cce0239baa4c04ca5bbabac4df000000ffff0300504b01022d0014000600080000002100e9de0fbfff0000001c020000130000000000000000
0000000000000000005b436f6e74656e745f54797065735d2e786d6c504b01022d0014000600080000002100a5d6a7e7c0000000360100000b00000000000000
000000000000300100005f72656c732f2e72656c73504b01022d00140006000800000021006b799616830000008a0000001c0000000000000000000000000019
0200007468656d652f7468656d652f7468656d654d616e616765722e786d6c504b01022d001400060008000000210096b5ade296060000501b00001600000000
000000000000000000d60200007468656d652f7468656d652f7468656d65312e786d6c504b01022d00140006000800000021000dd1909fb60000001b01000027
00000000000000000000000000a00900007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73504b050600000000050005005d0100009b0a00000000}
{\*\colorschememapping 3c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d22796573223f3e0d0a3c613a636c724d
617020786d6c6e733a613d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f64726177696e676d6c2f323030362f6d6169
6e22206267313d226c743122207478313d22646b3122206267323d226c743222207478323d22646b322220616363656e74313d22616363656e74312220616363
656e74323d22616363656e74322220616363656e74333d22616363656e74332220616363656e74343d22616363656e74342220616363656e74353d22616363656e74352220616363656e74363d22616363656e74362220686c696e6b3d22686c696e6b2220666f6c486c696e6b3d22666f6c486c696e6b222f3e}
{\*\latentstyles\lsdstimax371\lsdlockeddef0\lsdsemihiddendef0\lsdunhideuseddef0\lsdqformatdef0\lsdprioritydef99{\lsdlockedexcept \lsdqformat1 \lsdpriority0 \lsdlocked0 Normal;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 1;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 2;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 3;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 4;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 5;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 6;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 7;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 8;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 9;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 1;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 2;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 3;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 4;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 5;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 6;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 7;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 8;\lsdsemihidden1 \lsdunhideused1 \lsdpriority39 \lsdlocked0 toc 9;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority35 \lsdlocked0 caption;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List Number;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 4;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 List 5;\lsdqformat1 \lsdpriority10 \lsdlocked0 Title;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority1 \lsdlocked0 Default Paragraph Font;\lsdqformat1 \lsdpriority11 \lsdlocked0 Subtitle;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Salutation;\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Date;
\lsdsemihidden1 \lsdunhideused1 \lsdlocked0 Body Text First Indent;\lsdqformat1 \lsdpriority22 \lsdlocked0 Strong;\lsdqformat1 \lsdpriority20 \lsdlocked0 Emphasis;\lsdpriority59 \lsdlocked0 Table Grid;\lsdsemihidden1 \lsdlocked0 Placeholder Text;
\lsdqformat1 \lsdpriority1 \lsdlocked0 No Spacing;\lsdpriority60 \lsdlocked0 Light Shading;\lsdpriority61 \lsdlocked0 Light List;\lsdpriority62 \lsdlocked0 Light Grid;\lsdpriority63 \lsdlocked0 Medium Shading 1;\lsdpriority64 \lsdlocked0 Medium Shading 2;
\lsdpriority65 \lsdlocked0 Medium List 1;\lsdpriority66 \lsdlocked0 Medium List 2;\lsdpriority67 \lsdlocked0 Medium Grid 1;\lsdpriority68 \lsdlocked0 Medium Grid 2;\lsdpriority69 \lsdlocked0 Medium Grid 3;\lsdpriority70 \lsdlocked0 Dark List;
\lsdpriority71 \lsdlocked0 Colorful Shading;\lsdpriority72 \lsdlocked0 Colorful List;\lsdpriority73 \lsdlocked0 Colorful Grid;\lsdpriority60 \lsdlocked0 Light Shading Accent 1;\lsdpriority61 \lsdlocked0 Light List Accent 1;
\lsdpriority62 \lsdlocked0 Light Grid Accent 1;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 1;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 1;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 1;\lsdsemihidden1 \lsdlocked0 Revision;
\lsdqformat1 \lsdpriority34 \lsdlocked0 List Paragraph;\lsdqformat1 \lsdpriority29 \lsdlocked0 Quote;\lsdqformat1 \lsdpriority30 \lsdlocked0 Intense Quote;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 1;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 1;
\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 1;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 1;\lsdpriority70 \lsdlocked0 Dark List Accent 1;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 1;\lsdpriority72 \lsdlocked0 Colorful List Accent 1;
\lsdpriority73 \lsdlocked0 Colorful Grid Accent 1;\lsdpriority60 \lsdlocked0 Light Shading Accent 2;\lsdpriority61 \lsdlocked0 Light List Accent 2;\lsdpriority62 \lsdlocked0 Light Grid Accent 2;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 2;
\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 2;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 2;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 2;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 2;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 2;
\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 2;\lsdpriority70 \lsdlocked0 Dark List Accent 2;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 2;\lsdpriority72 \lsdlocked0 Colorful List Accent 2;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 2;
\lsdpriority60 \lsdlocked0 Light Shading Accent 3;\lsdpriority61 \lsdlocked0 Light List Accent 3;\lsdpriority62 \lsdlocked0 Light Grid Accent 3;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 3;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 3;
\lsdpriority65 \lsdlocked0 Medium List 1 Accent 3;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 3;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 3;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 3;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 3;
\lsdpriority70 \lsdlocked0 Dark List Accent 3;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 3;\lsdpriority72 \lsdlocked0 Colorful List Accent 3;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 3;\lsdpriority60 \lsdlocked0 Light Shading Accent 4;
\lsdpriority61 \lsdlocked0 Light List Accent 4;\lsdpriority62 \lsdlocked0 Light Grid Accent 4;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 4;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 4;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 4;
\lsdpriority66 \lsdlocked0 Medium List 2 Accent 4;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 4;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 4;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 4;\lsdpriority70 \lsdlocked0 Dark List Accent 4;
\lsdpriority71 \lsdlocked0 Colorful Shading Accent 4;\lsdpriority72 \lsdlocked0 Colorful List Accent 4;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 4;\lsdpriority60 \lsdlocked0 Light Shading Accent 5;\lsdpriority61 \lsdlocked0 Light List Accent 5;
\lsdpriority62 \lsdlocked0 Light Grid Accent 5;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 5;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 5;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 5;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 5;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 5;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 5;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 5;\lsdpriority70 \lsdlocked0 Dark List Accent 5;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 5;
\lsdpriority72 \lsdlocked0 Colorful List Accent 5;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 5;\lsdpriority60 \lsdlocked0 Light Shading Accent 6;\lsdpriority61 \lsdlocked0 Light List Accent 6;\lsdpriority62 \lsdlocked0 Light Grid Accent 6;
\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 6;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 6;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 6;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 6;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 6;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 6;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 6;\lsdpriority70 \lsdlocked0 Dark List Accent 6;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 6;
\lsdpriority72 \lsdlocked0 Colorful List Accent 6;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 6;\lsdqformat1 \lsdpriority19 \lsdlocked0 Subtle Emphasis;\lsdqformat1 \lsdpriority21 \lsdlocked0 Intense Emphasis;
\lsdqformat1 \lsdpriority31 \lsdlocked0 Subtle Reference;\lsdqformat1 \lsdpriority32 \lsdlocked0 Intense Reference;\lsdqformat1 \lsdpriority33 \lsdlocked0 Book Title;\lsdsemihidden1 \lsdunhideused1 \lsdpriority37 \lsdlocked0 Bibliography;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority39 \lsdlocked0 TOC Heading;\lsdpriority41 \lsdlocked0 Plain Table 1;\lsdpriority42 \lsdlocked0 Plain Table 2;\lsdpriority43 \lsdlocked0 Plain Table 3;\lsdpriority44 \lsdlocked0 Plain Table 4;
\lsdpriority45 \lsdlocked0 Plain Table 5;\lsdpriority40 \lsdlocked0 Grid Table Light;\lsdpriority46 \lsdlocked0 Grid Table 1 Light;\lsdpriority47 \lsdlocked0 Grid Table 2;\lsdpriority48 \lsdlocked0 Grid Table 3;\lsdpriority49 \lsdlocked0 Grid Table 4;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 1;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 1;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 1;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 1;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 1;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 2;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 2;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 2;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 2;
\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 3;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 3;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 3;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 3;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 3;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 4;
\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 4;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 4;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 4;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 4;
\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 4;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 5;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 5;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 5;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 5;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 5;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 6;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 6;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 6;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 6;
\lsdpriority46 \lsdlocked0 List Table 1 Light;\lsdpriority47 \lsdlocked0 List Table 2;\lsdpriority48 \lsdlocked0 List Table 3;\lsdpriority49 \lsdlocked0 List Table 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful;\lsdpriority52 \lsdlocked0 List Table 7 Colorful;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 List Table 2 Accent 1;\lsdpriority48 \lsdlocked0 List Table 3 Accent 1;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 1;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 1;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 1;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 List Table 2 Accent 2;\lsdpriority48 \lsdlocked0 List Table 3 Accent 2;\lsdpriority49 \lsdlocked0 List Table 4 Accent 2;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 2;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 3;
\lsdpriority47 \lsdlocked0 List Table 2 Accent 3;\lsdpriority48 \lsdlocked0 List Table 3 Accent 3;\lsdpriority49 \lsdlocked0 List Table 4 Accent 3;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 3;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 4;\lsdpriority47 \lsdlocked0 List Table 2 Accent 4;
\lsdpriority48 \lsdlocked0 List Table 3 Accent 4;\lsdpriority49 \lsdlocked0 List Table 4 Accent 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 4;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 4;
\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 List Table 2 Accent 5;\lsdpriority48 \lsdlocked0 List Table 3 Accent 5;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 5;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 5;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 5;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 List Table 2 Accent 6;\lsdpriority48 \lsdlocked0 List Table 3 Accent 6;\lsdpriority49 \lsdlocked0 List Table 4 Accent 6;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 6;}}{\*\datastore 010500000200000018000000
4d73786d6c322e534158584d4c5265616465722e362e3000000000000000000000060000
d0cf11e0a1b11ae1000000000000000000000000000000003e000300feff090006000000000000000000000001000000010000000000000000100000feffffff00000000feffffff0000000000000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
fffffffffffffffffdfffffffeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff
ffffffffffffffffffffffffffffffff52006f006f007400200045006e00740072007900000000000000000000000000000000000000000000000000000000000000000000000000000000000000000016000500ffffffffffffffffffffffff0c6ad98892f1d411a65f0040963251e50000000000000000000000003012
e7c7a51cd701feffffff00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff00000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff0000000000000000000000000000000000000000000000000000
000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff000000000000000000000000000000000000000000000000
0000000000000000000000000000000000000000000000000105000000000000}}